Back to results

TerminatedPhase 1

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05576077

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

University of California Irvine

Irvine, California, United States

+12 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2023-01-17
Enrollment: 31 participants
Sponsor: Turnstone Biologics, Corp.
Purpose: treatment

Locations (13)

University of California IrvineIrvine, California, United States
Memorial Healthcare SystemHollywood, Florida, United States
University of MiamiMiami, Florida, United States
Orlando HealthOrlando, Florida, United States
Moffitt Cancer CenterTampa, Florida, United States
University of ChicagoChicago, Illinois, United States
Norton Cancer InstituteLouisville, Kentucky, United States
Providence Cancer InstitutePortland, Oregon, United States
Allegheny Research InstitutePittsburgh, Pennsylvania, United States
MD Anderson Cancer CenterHouston, Texas, United States
Medical College of WisconsinMilwaukee, Wisconsin, United States
Princess Margaret Cancer CentreToronto, Ontario, Canada
Montreal University Hospital CenterMontreal, Quebec, Canada

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors — TrialFind